uracil has been researched along with nevirapine in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (43.75) | 18.2507 |
| 2000's | 6 (37.50) | 29.6817 |
| 2010's | 3 (18.75) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Duffy, EM; Jorgensen, WL | 1 |
| Du-Cuny, L; Mash, EA; Meuillet, EJ; Moses, S; Powis, G; Song, Z; Zhang, S | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Cheng, YC; Chu, SH; Dutschman, GE; Im, GJ; Pan, BC; Piras, G | 1 |
| Bader, JP; Boyer, PL; Buckheit, RW; Chu, SH; Fliakas-Boltz, V; Hughes, SH; Mayers, DL; Pan, BC; Weislow, O; Yeagy-Bargo, S | 1 |
| Brennan, TM; Bridges, CG; Leyda, JP; Taylor, DL; Tyms, AS | 1 |
| Baba, M; Makino, M; Nakade, K; Okamoto, M; Yamada, K; Yuasa, S | 1 |
| Fujiwara, T; Hayami, M; Isaka, Y; Kawauchi, S; Miki, S; Sato, A; Suyama, A | 1 |
| Griffith, R; Keller, PA; Titmuss, SJ | 1 |
| Crowe, S | 1 |
| Balzarini, J; Burt, V; Carbonez, A; De Clercq, E; Kleim, JP | 1 |
| Jorgensen, WL; Rizzo, RC; Tirado-Rives, J | 1 |
| Jorgensen, WL; Kroeger Smith, MB; Rizzo, RC; Smith, RH; Tirado-Rives, J; Udier-Blagović, M; Wang, DP; Watkins, EK | 1 |
| Andries, K; Benjahad, A; Bisagni, E; Coupa, S; Courté, K; Csoka, I; de Béthune, MP; Grierson, DS; Guillemont, J; Mabire, D; Monneret, C; Nguyen, CH; Pauwels, R; Poncelet, A | 1 |
| Decha, P; Hannongbua, S; Intharathep, P; Parasuk, V; Sompornpisut, P; Udommaneethanakit, T; Wolschann, P | 1 |
| Baba, M; Demizu, Y; Irie, K; Kato, Y; Kurihara, M; Maruyama, T; Misawa, T; Okamoto, M; Sakakibara, N; Toyama, M | 1 |
1 review(s) available for uracil and nevirapine
| Article | Year |
|---|---|
New reverse transcriptase inhibitors.
Topics: Adenine; Alkynes; Benzoxazines; Cyclopropanes; Delavirdine; Dideoxynucleosides; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Nevirapine; Organophosphonates; Oxazines; Prodrugs; Reverse Transcriptase Inhibitors; Soman; Uracil | 1999 |
15 other study(ies) available for uracil and nevirapine
| Article | Year |
|---|---|
Prediction of drug solubility from Monte Carlo simulations.
Topics: Monte Carlo Method; Pharmaceutical Preparations; Solubility | 2000 |
Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.
Topics: Antineoplastic Agents; Blood Proteins; Caco-2 Cells; Cell Membrane Permeability; Computer Simulation; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Phosphoproteins; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-akt; Quantitative Structure-Activity Relationship | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Action of uracil analogs on human immunodeficiency virus type 1 and its reverse transcriptase.
Topics: Antiviral Agents; HIV Reverse Transcriptase; HIV-1; Nevirapine; Pyridines; Reverse Transcriptase Inhibitors; Uracil | 1995 |
Resistance to 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives is generated by mutations at multiple sites in the HIV-1 reverse transcriptase.
Topics: Antiviral Agents; Cell Line; Dose-Response Relationship, Drug; Drug Resistance, Microbial; HIV Reverse Transcriptase; HIV-1; HIV-2; Humans; Mutagenesis, Site-Directed; Nevirapine; Pyridines; Recombinant Proteins; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Structure-Activity Relationship; Thymine; Uracil; Zidovudine | 1995 |
The inhibition of human immunodeficiency virus type 1 in vitro by a non-nucleoside reverse transcriptase inhibitor MKC-442, alone and in combination with other anti-HIV compounds.
Topics: Antiviral Agents; Cells, Cultured; Cytotoxicity Tests, Immunologic; Didanosine; Drug Interactions; HIV Reverse Transcriptase; HIV-1; Humans; Indolizines; Isoquinolines; Leukocytes, Mononuclear; Molecular Structure; Nevirapine; Pyridines; Quinolines; Reverse Transcriptase Inhibitors; Saquinavir; Uracil; Zalcitabine; Zidovudine | 1995 |
Complete inhibition of viral breakthrough by combination of MKC-442 with AZT during a long-term culture of HIV-1 infected cells.
Topics: Acetamides; Acetophenones; Cell Line, Transformed; HIV; HIV Core Protein p24; HIV-1; Humans; Nevirapine; Pyridines; Reverse Transcriptase Inhibitors; Uracil; Zidovudine | 1996 |
Construction of the chimeric reverse transcriptase of simian immunodeficiency virus sensitive to nonnucleoside reverse transcriptase inhibitor.
Topics: Amino Acid Sequence; Benzodiazepines; Cells, Cultured; HIV Reverse Transcriptase; HIV-1; Humans; Imidazoles; Kinetics; Molecular Sequence Data; Nevirapine; Reassortant Viruses; Recombinant Fusion Proteins; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Simian Immunodeficiency Virus; Transfection; Uracil | 1998 |
Docking experiments in the flexible non-nucleoside inhibitor binding pocket of HIV-1 reverse transcriptase.
Topics: Binding Sites; Databases, Factual; HIV; HIV Reverse Transcriptase; Ligands; Molecular Structure; Nevirapine; Protein Conformation; Reproducibility of Results; Reverse Transcriptase Inhibitors; Uracil | 1999 |
Long-term exposure of HIV type 1-infected cell cultures to combinations of the novel quinoxaline GW420867X with lamivudine, abacavir, and a variety of nonnucleoside reverse transcriptase inhibitors.
Topics: Alkynes; Anilides; Anti-HIV Agents; Benzoxazines; Cell Line; Cyclopropanes; Delavirdine; Dideoxynucleosides; Dose-Response Relationship, Drug; Drug Combinations; Drug Resistance, Microbial; Furans; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Microbial Sensitivity Tests; Mutation; Nevirapine; Oxazines; Quinoxalines; Reverse Transcriptase Inhibitors; Thioamides; Uracil | 2000 |
Estimation of binding affinities for HEPT and nevirapine analogues with HIV-1 reverse transcriptase via Monte Carlo simulations.
Topics: Anti-HIV Agents; HIV Reverse Transcriptase; Models, Molecular; Monte Carlo Method; Nevirapine; Protein Binding; Pyrimidinones; Regression Analysis; Reverse Transcriptase Inhibitors; Thermodynamics; Uracil | 2001 |
Prediction of activity for nonnucleoside inhibitors with HIV-1 reverse transcriptase based on Monte Carlo simulations.
Topics: Alkynes; Anilides; Benzoxazines; Computer Simulation; Cyclopropanes; HIV Reverse Transcriptase; Hydrogen Bonding; Models, Molecular; Monte Carlo Method; Nevirapine; Oxazines; Protein Binding; Quinoxalines; Regression Analysis; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Uracil | 2002 |
4-benzyl- and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones, a new family of potent anti-HIV agents: optimization and in vitro evaluation against clinically important HIV mutant strains.
Topics: Alkynes; Aminopyridines; Anti-HIV Agents; Benzene Derivatives; Benzoates; Benzoxazines; Cell Line; Cyclopropanes; HIV-1; Humans; Mutagenesis, Site-Directed; Mutation; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Uracil | 2004 |
Theoretical studies on the molecular basis of HIV-1RT/NNRTIs interactions.
Topics: Alkynes; Amino Acids; Benzoxazines; Binding Sites; Cyclopropanes; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Models, Biological; Molecular Dynamics Simulation; Mutation; Nevirapine; Nitriles; Protein Binding; Protein Conformation; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Thermodynamics; Uracil; Water | 2011 |
Design, synthesis, and anti-HIV-1 activity of 1-aromatic methyl-substituted 3-(3,5-dimethylbenzyl)uracil and N-3,5-dimethylbenzyl-substituted urea derivatives.
Topics: Anti-HIV Agents; Binding Sites; Cell Line; Chemistry Techniques, Synthetic; Drug Design; HIV Reverse Transcriptase; HIV-1; Molecular Docking Simulation; Nevirapine; Protein Conformation; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Uracil; Urea | 2015 |